{"id":"fluoxetine-outpatient-cognitive-behavioral-therapy","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-20","effect":"Sexual dysfunction"},{"rate":"5-10","effect":"Anxiety (initial)"},{"rate":"5-10","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL1201082","moleculeType":"Small molecule","molecularWeight":"345.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the reuptake of serotonin at the synaptic cleft, increasing serotonin concentration and improving mood regulation. Cognitive behavioral therapy (CBT) is a structured psychotherapeutic intervention that helps patients recognize negative thought patterns and develop coping strategies. The combination leverages both pharmacological and behavioral approaches to treat psychiatric conditions more effectively than either modality alone.","oneSentence":"Fluoxetine increases serotonin availability in the brain while cognitive behavioral therapy teaches patients to identify and modify maladaptive thought patterns and behaviors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:40.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Panic disorder"},{"name":"Substance use disorders (in research/clinical settings)"}]},"trialDetails":[{"nctId":"NCT01740752","phase":"NA","title":"UCAN2: Uniting Couples in the Treatment of Anorexia Nervosa","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-07","conditions":"Anorexia Nervosa","enrollment":70},{"nctId":"NCT00061113","phase":"PHASE4","title":"Substance Dependent Teens - Impact of Treating Depression Study 1 - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-02","conditions":"Alcohol-Related Disorders, Marijuana Abuse, Substance-Related Disorders","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prozac"],"phase":"marketed","status":"active","brandName":"Fluoxetine + outpatient cognitive behavioral therapy","genericName":"Fluoxetine + outpatient cognitive behavioral therapy","companyName":"National Institute on Drug Abuse (NIDA)","companyId":"national-institute-on-drug-abuse-nida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluoxetine increases serotonin availability in the brain while cognitive behavioral therapy teaches patients to identify and modify maladaptive thought patterns and behaviors. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}